Protagonist Therapeutics PTGX Increase Decrease In Receivables From Collaboration Partner
Increase Decrease In Receivables From Collaboration Partner at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept ptgx:IncreaseDecreaseInReceivablesFromCollaborationPartner.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's increase decrease in receivables from collaboration partner.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's increase decrease in receivables from collaboration partner?
- Protagonist Therapeutics (PTGX) reported increase decrease in receivables from collaboration partner of $53.54M in Q1 2026.
- How has Protagonist Therapeutics's increase decrease in receivables from collaboration partner changed year-over-year?
- Protagonist Therapeutics's increase decrease in receivables from collaboration partner increased by 132.4% year-over-year, from -$165M to $53.54M.
- What does increase decrease in receivables from collaboration partner mean?
- This captures the change in outstanding balances owed by collaboration partners for services or milestones performed under research and development agreements. A significant increase indicates that revenue has been recognized but not yet collected, impacting short-term operating cash flow. It serves as a key indicator of the timing and realization of cash from strategic biopharmaceutical partnerships.